Schermer T R J, Hendriks A J C, Chavannes N H, Dekhuijzen P N R, Wouters E F M, van den Hoogen H, van Schayck C P, van Weel C
Department of General Practice/Family Medicine, University Medical Centre Nijmegen, 229-HAG, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Prim Care Respir J. 2004 Mar;13(1):48-55. doi: 10.1016/j.pcrj.2003.11.005.
The objective of the study was to assess the probability, and explore determinants of adverse respiratory outcome after discontinuation of inhaled corticosteroid (ICS) treatment in subjects with chronic obstructive pulmonary disease (COPD) diagnosed and treated in general practice.
Prospective unblinded ICS withdrawal study.
201 ICS treated COPD patients with various degrees of airflow limitation from 45 Dutch general practices.
Probability of and time to exacerbation or unremitting worsening of respiratory symptoms after ICS discontinuation.
Mean age was 60.6 (S.D. 9.5) years, post-bronchodilator forced expiratory volume in 1s (FEV1) 65.6 (S.D. 15.7) % predicted. Overall probability of adverse respiratory outcome after ICS discontinuation was 0.37 (95% confidence interval (CI) 0.31, 0.44). Survival analysis showed that age, gender, smoking status and reversibility of airflow limitation were independent predictors of adverse respiratory outcome. For females, the adjusted hazard ratio was 2.14 (95% CI 1.31, 3.50) compared to males. For age, the hazard ratio was 1.05 (95% CI 1.02, 1.08) per year lived.
Discontinuation of inhaled corticosteroids may harm patients with COPD. The probability of an adverse respiratory outcome may be higher in women, elderly patients, smokers and patients with higher bronchodilator reversibility while on inhaled steroid treatment.
本研究的目的是评估在全科医疗中诊断和治疗的慢性阻塞性肺疾病(COPD)患者停用吸入性糖皮质激素(ICS)治疗后出现不良呼吸结局的可能性,并探讨其决定因素。
前瞻性非盲法ICS撤药研究。
来自45家荷兰全科医疗诊所的201例接受ICS治疗的不同程度气流受限的COPD患者。
停用ICS后呼吸症状加重或持续恶化的可能性及时间。
平均年龄为60.6(标准差9.5)岁,支气管扩张剂后1秒用力呼气容积(FEV1)为预测值的65.6(标准差15.7)%。停用ICS后不良呼吸结局的总体概率为0.37(95%置信区间(CI)0.31,0.44)。生存分析表明,年龄、性别、吸烟状况和气流受限的可逆性是不良呼吸结局的独立预测因素。与男性相比,女性调整后的风险比为2.14(95%CI 1.31,3.50)。对于年龄,每年的风险比为1.05(95%CI 1.02,1.08)。
停用吸入性糖皮质激素可能对COPD患者有害。在女性、老年患者、吸烟者以及吸入类固醇治疗时支气管扩张剂可逆性较高的患者中,出现不良呼吸结局的可能性可能更高。